TNB Tech Minute: FDA Reverses Rejection of Another Rare-Disease Drug

2026-06-22 · Source: WSJ Tech News Briefing · Field: Technology & Digital — Artificial Intelligence & Machine Learning, Robotics & Autonomous Systems, Pharmaceuticals & Biotechnology · Depth: Fundamental Awareness, quick

Summary

The TNB Tech Minute for Monday, June 22nd, reports on three key developments. The US Food and Drug Administration has reversed its rejection of RegenX Bio's experimental gene therapy for Hunter syndrome, a rare genetic disease, marking a broader shift away from demanding placebo-controlled trials for rare disease drugs. Concurrently, Chevron has secured a 20-year agreement with Microsoft to supply electricity for a major AI data center in West Texas, utilizing natural gas and an on-site power plant, positioning Chevron as a leader in the data center energy market. Additionally, Kua, a Chinese robotics company backed by SoftBank Group, is preparing for an initial public offering in Hong Kong within the next two to three months, with a valuation exceeding \$3 billion, focusing on embodied AI robots for urban applications like shared mobility and manufacturing.

Key takeaway

For investors tracking biotech and AI infrastructure, you should note the FDA's evolving stance on rare disease drug approvals, potentially easing market entry for certain therapies. Chevron's 20-year deal with Microsoft highlights the growing demand for dedicated energy solutions for AI data centers, signaling a lucrative sector for energy providers. Furthermore, the impending Kua IPO in Hong Kong indicates robust investor confidence in embodied AI robotics, suggesting you evaluate opportunities in this rapidly expanding market segment.

Key insights

Regulatory shifts, energy deals, and robotics IPOs signal dynamic tech and biotech market movements.

Principles

• FDA policy shifts impact rare disease drug development.
• Energy companies are capitalizing on AI data center demand.
• Embodied AI robotics attracts significant investment.

In practice

• Monitor FDA's evolving stance on rare disease trials.
• Evaluate energy infrastructure for AI data center growth.
• Track SoftBank-backed robotics IPOs for market trends.

Topics

• FDA Regulation
• Gene Therapy
• AI Data Centers
• Energy Infrastructure
• Robotics IPO
• Embodied AI

Best for: CTO, VP of Engineering/Data, Director of AI/ML, Tech Journalist, Investor, Executive

Related on AIssential

• TNB Tech Minute: Google Strikes AI Deal With Pentagon — AI is being integrated into sensitive government sectors and critical regulatory processes, with defined usage boundaries.
• Energy IPOs surge as investors hunt for ways to play AI boom — AI's energy demands are fueling a speculative surge in energy IPOs, attracting investors despite high post-IPO volatility.
• TNB Tech Minute: TeraWulf Partners with Anthropic on $19 Billion AI-Infrastructure Campus — Digital infrastructure company TeraWulf is partnering with Anthropic to build a Kentucky-based AI-infrastructure campus, projected to generate \$19 billion in revenue and bring 400 megawatts of comput…
• Oracle, OpenAI End Plans to Expand Flagship Data Center — Geopolitical tensions and AI industry dynamics are reshaping energy markets, defense tech, and data center infrastructure.
• The Week’s 10 Biggest Funding Rounds: World Labs Leads Another AI-Heavy Lineup — AI, fintech, and energy tech dominate recent U.S. startup megadeals, with World Labs securing $1 billion.
• The IPO Pipeline Finally Gets Interesting — The IPO market is seeing a resurgence across diverse sectors, excluding enterprise software.

See Counsel's argued verdicts on the open AI decisions leaders are weighing →

Open in AIssential →

Editorial summary, takeaway, and curation by AIssential. Original article published by WSJ Tech News Briefing.